Table 3.

Breakdown and description of the toxicities of IT nivolumab by IT nivolumab dose level as well as for the individual patient. After the first cycle (IT nivolumab alone), assignment of toxicity to either IT, IV or IT/IV nivolumab was inherently more difficult, as IV and IT nivolumab were administered within 24 h of each other

IT nivolumab dose	Patient Accession Number	Adverse event	Cycle number	Grade 1	Grade 2
5 mg	1	Paresthesia	11	1
		Aphasia	19		1
20 mg	8	Neck pain	1		1
	10	Nausea	1	1
	19	Nausea	1	1
	20a	Dizziness	1	1
		Nausea	1	1
50 mg	24	Pruritus	1	1
		Nausea	1	1
	25a	Dizziness	1	1
		Paresthesia	1	1
		Vomiting	1	1
		Nausea	16	1
	26	Anorexia	1	1
		Dizziness	1	1
		Nausea	1	1
		Vomiting	1	1
	27a	Nausea	1	1
		Dizziness	1	1
		Vomiting	1	1
	30aa	Visual changes	1	1

^aOn concurrent treatment with BRAF/MEK inhibitor.